#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Extraskeletal ossification Ocular lymphoma Crohn's disease Dermatomyositis B-cell small lymphocytic lymphoma refractory Dementia Glomerulonephritis membranoproliferative Leukodystrophy Prolymphocytic leukaemia Acquired ATTR amyloidosis Renal cell carcinoma Retinitis pigmentosa Pyruvate kinase deficiency anaemia Biotinidase deficiency SAPHO syndrome More trials…

    Learn about Rare Diseases

    MELAS syndrome – Trials in Disease Small intestine leiomyosarcoma Primary immunodeficiency syndrome – Trials in Disease Noonan syndrome – Diagnostics Von Willebrand’s disease – Life with Disease Mastocytosis Arterial tortuosity syndrome – Treatment Von Willebrand’s disease – Diagnostics Idiopathic inflammatory myopathy – Life with Disease Alveolar rhabdomyosarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Thiamine ALN-4324 Mk-1942 SODIUM BENZOATE Alfacalcidol Nedosiran Apl-101 Sodium Glycocholate Somatostatin Paroxetine Skin Autograft Clemizole Hydrochloride Sodium Chloride Ph. Eur. Dronabinol Carvedilol Rct2100 Palbociclib Salbutamol Sulfate Ph. Eur. Piperacillin Calcium Chloride Hexahydrate More therapies…

    Learn about Your Condition

    Arterial disorder Haemophilia Cushing's syndrome Hydrocephalus Stress Squamous cell carcinoma Intellectual disability Dry mouth Right ventricular dysfunction Neoplasm Burning mouth syndrome Limb reduction defect Cancer pain Pyelonephritis acute Autoimmune haemolytic anaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study of immune response and biomarkers in patients with metastatic solid tumors treated with BMS-986340 and nivolumab

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    • Adenocarcinoma gastric
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bms-986340
    • Nivolumab
    Italy

  • Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Taletrectinib
    Belgium France Germany Italy Spain

  • Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    • Neoplasm malignant
    • Non-small cell lung cancer
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
    • Carboplatin
    Belgium France Germany Greece Ireland Italy +3

  • Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cemiplimab
    The Netherlands

  • DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Cervix carcinoma
    • Hepatocellular carcinoma
    • Ovarian cancer
    Investigated Drugs:
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3′,4′:6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE
    • BNT327
    France Germany Italy Poland Spain

  • Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pemetrexed Disodium
    • Carboplatin
    • Pembrolizumab
    France
Previous Page
1 … 17 18 19 20 21 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!